Skinvisible plans second trial of hand sanitizer to show persistency

New York, Feb. 2 - Skinvisible, Inc. said it will commission a second trial of its patent pending chlorhexidine hand sanitizer.

This additional study is intended to demonstrate that the chemical remains on the hands for an extended period of time, resisting being washed or rubbed off.

The first trial showed that chlorhexidine had a greater than 99% kill of the bird flu virus H5N1 at 15 seconds, 30 seconds, one minute and five minutes after application.

Retroscreen Virology Ltd., a European contract research company, will carry out the second test, as it did the first.

Skinvisible is a Las Vegas research and development company that has formulated and patented innovative polymer delivery system technology and compositions for topical skin applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.